Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019

ROYAL LANCASTER LONDON

Are We Ready for a $5m Gene Therapy?

Are We Ready for a $5m Gene Therapy?

Episode two of the Phacilitate Leaders World super plenary sessions with Dave Lennon, President of Avexis, Inc

Episode two of the Phacilitate Leaders World super plenary discussions sees Anthony Davies quizzing Dave Lennon, President of AveXis about the projected cost of (the now FDA-approved) Zolgensma, which, at the time of filming was in the $4-5m range.

However, the reported cost upon FDA approval last week of $2.1m per patient has further pushed the drug pricing boundaries, paving the way for a new era of pricing and reimbursement.

So, how does this compare to the spend of our healthcare on caring for long-term diseases? Think dialysis, enzyme replacement therapies, oligonucleotide therapies and the like... Dave gives his take on this, ICER's health economics evaluation and how they are working with the healthcare system and payers around reimbursement from instalment plans to amortisation.

Anthony also gives some insight into his research, which hypothesised that if the three recently approved advanced therapies (Kymriah, Yescarta, Luxterna) reached 100% market penetrance at current North American pricing then the effect of that on North American drug spend would be LESS than a 0.1% increase. A comparable situation at 20% had the spend more than double.

Watch the interview to hear more about pricing, dosing challenges, AveXis' approach to manufacturing and more.

 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd